• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Mainstay Medical

FDA approves Mainstay Medical neurostim device

June 23, 2020 By Sean Whooley

Mainstay Medical announced that it received FDA premarket approval for its ReActiv8 implantable neurostimulation system for chronic low back pain. ReActiv8 treats intractable chronic low back pain associated with multifidus muscle dysfunction, as evidenced by imaging or physiological testing in adults who have failed therapy and are not candidates for spine surgery, according to a […]

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), Implants, Neurological, Neuromodulation/Neurostimulation, Pain Management, Pre-Market Approval (PMA), Regulatory/Compliance, Spine Tagged With: FDA, Mainstay Medical

Smith & Nephew CEO Bohuon to retire | Personnel Moves – Oct. 10, 2017

October 10, 2017 By Fink Densford

Smith & Nephew (NYSE:SNN) said today that its current CEO Olivier Bohuon has announced his intention to retire by the end of 2018 and that the company has begun a search for a new chief exec. Bohuon joined the company in 2011, and has overseen a significant rise in share value with the company since taking the […]

Filed Under: Business/Financial News Tagged With: Invacare, Mainstay Medical, Nuvasive, Philips, prometrika, Smith & Nephew, transmed7

Mainstay Medical taps ex-NuVasive COO Hannon for CEO | Personnel Moves, Sept. 7, 2017

September 7, 2017 By Brad Perriello

Mainstay Medical (EPA:MSTY) said this week that it tapped former NuVasive Inc. (NSDQ:NUVA) president & COO Jason Hannon to succeed Peter Crosby as CEO, effective Oct. 9. Crosby, recruited in 2009 to lead the company and its development of the Reactiv8 neurostimulation device for treating chronic pain, is slated to act as a consultant for Mainstay through […]

Filed Under: Wall Street Beat Tagged With: AdvaMed, avitamedical, Axonics Modulation Technologies, lightmed, Mainstay Medical, Monarch Medical, qholding, venturemed

Mainstay Medical pulls in $34m for Reactiv8 neurostim device for chronic pain

June 20, 2016 By Brad Perriello

Mainstay Medical (EPA:MSTY) said last week that it raised a $34 million (€30 million) equity round for its Reactiv8 neurostimulation device, including a $17 million (€15 million) contribution from family investment fund KCK. Proceeds from the 2.3-million-share flotation, priced at $14.70 apiece (€13.00), are slated for European commercialization of the Reactiv8 device (the system won CE Mark approval in […]

Filed Under: Funding Roundup, Neuromodulation/Neurostimulation, Pain Management Tagged With: Capricorn Venture Partners, Fountain Healthcare Partners, IPF Partners, Mainstay Medical, Sofinnova Partners

Mainstay Medical wins CE Mark for ReActiv8 neurostim

May 25, 2016 By Fink Densford

Mainstay Medical (EPA:MSTY) said today it won CE Mark approval for its ReActiv8 implantable neurostimulation system designed to treat chronic lower back pain. The device was approved based off data from the company’s ReActiv8-A trial, which reported statistically significant, lasting improvements in pain, disability and quality of life in patients with chronic low back pain and […]

Filed Under: Neuromodulation/Neurostimulation, Regulatory/Compliance Tagged With: Mainstay Medical

Mainstay: ReActiv8 data may be enough for CE Mark, announces earnings

August 31, 2015 By Fink Densford

Mainstay Medical (EPA:MSTY) said that data from a trial of its ReActiv8 neurostim may be enough to win it CE Mark approval in the European Union and released its 6-month earnings today. The company’s multi-center, prospective ReActiv8-A clinical trial examined patients with chronic lower back pain treated with the company’s implantable ReActiv8 neurostimulation device. Of the […]

Filed Under: Business/Financial News, Clinical Trials, MassDevice Earnings Roundup, Neuromodulation/Neurostimulation Tagged With: Mainstay Medical

Mainstay Medical raises $15m

August 25, 2015 By Fink Densford

Mainstay Medical (EPA:MSTY) said yesterday it raised $15 million in a debt financing round to help fund its ReActiv8 implantable device for individuals with chronic low back pain. The debt facility came from IPF Partners, according to Dublin, Ireland-based Mainstay. “We are pleased to have secured this $15 million debt facility. These funds strengthen our financial […]

Filed Under: Business/Financial News, Neuromodulation/Neurostimulation, Pain Management Tagged With: Mainstay Medical

Report: Mainstay Medical’s IPO raises $25M

May 1, 2014 By Brad Perriello Leave a Comment

Report: Mainstay Medical's IPO raises $25M

Mainstay Medical‘s (MSTY.PA) European initial public offering reeled in about $25 million (€18 million) and made the spinal implant maker the 1st medtech company to float an IPO in Paris and the 1st company to attempt a dual flotation in Paris and Dublin, the Irish Times reports.

Filed Under: Initial Public Offering (IPO), Neuromodulation/Neurostimulation, News Well, Pain Management, Spine, Wall Street Beat Tagged With: Mainstay Medical

Mainstay Medical readies European IPO

April 17, 2014 By Brad Perriello Leave a Comment

Mainstay Medical readies European IPO

Mainstay Medical is preparing an initial public offering on the EuroNext stock exchange that could be worth up to $42 million, according to a regulatory filing.

Mainstay, which last month launched a new clinical trial of its ReActiv8 implantable neurostimulator for chronic lower back pain, said it plans to offer some 1.1 million shares at €20-€27 per share, or about $27.77 to $37.50 per share.

Filed Under: Initial Public Offering (IPO), News Well, Spine, Wall Street Beat Tagged With: Mainstay Medical

Mainstay Medical launches human trial of pain-relief stimulation implant

March 12, 2014 By Arezu Sarvestani Leave a Comment

Mainstay Medical launches human trial of pain-relief stimulation implant

Dublin-based Mainstay Medical touted the launch of a new clinical trial evaluating its ReActiv8 implantable neurostimulator at 3 clinical sites in Australia.

Filed Under: Neuromodulation/Neurostimulation, News Well, Pain Management Tagged With: Clinical Trials, Mainstay Medical

Sony picks up 11% Olympus stake for $640M | Wall Street Beat

October 1, 2012 By MassDevice staff Leave a Comment

MassDevice.com Wall Street Beat

Sony Corp. (TYO:6758) plans to become the largest shareholder in Olympus (TYO:7733) with a $642 million investment that will give it an 11% stake in Olympus.

Filed Under: News Well, Wall Street Beat Tagged With: 180medical, BSD Medical Corp., ConvaTec, Mainstay Medical, Olympus, Sony Corp.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS